Nicardipine for rapid systolic BP control in intracerebral hemorrhage
Official title: NICardipine for Fast Achievement of Systolic BP Targets in ICH - a Quasi-randomized, Implementation Trial With Stepwise Rollout of Nicardipin Based Treatment of Hypertension.
Run by Aarhus University Hospital · NCT07044232 · Data updated 2026-11-12
This trial tests whether using intravenous nicardipine to quickly lower systolic blood pressure to under 140 mmHg within 1 hour helps adults with intracerebral hemorrhage.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 88 (estimated) |
| Sponsor | Aarhus University Hospital Academic / other |
| Locations | 1 site (Aarhus) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2027 |
| Registry record updated | June 24, 2026 |
| Trial ID | NCT07044232 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older with acute spontaneous intracerebral hemorrhage confirmed by imaging and SBP >140 mmHg on admission.
✕Probably not a fit
Patients whose blood pressure naturally falls quickly or who do not respond to intravenous antihypertensives may see no additional benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This quality improvement study uses a quasi-randomized design to implement a treatment algorithm that prioritizes intravenous antihypertensives like nicardipine over transdermal nitrate patches. The goal is to increase the proportion of patients reaching a systolic BP target of less than 140 mmHg within 1 hour of hospital admission while monitoring safety, clinical outcomes, and resource use. The approach reflects existing guideline emphasis on rapid BP control in acute ICH and builds on prior signals about potential harms from early nitrate patches. The study is conducted at Aarhus University Hospital with lead sponsorship from the same institution.
Why it matters
Potential benefit: If successful, patients with intracerebral hemorrhage could experience faster and safer blood pressure control, potentially reducing hematoma growth and improving outcomes.
How similar studies have gone: Previous randomized trials have supported rapid systolic BP reduction with intravenous agents, though safety signals have limited use of certain patches in the hyperacute phase.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Acute spontaneous Intracerberal Hemorrhage confirmed by imaging * Symptom onset to stroke center admission \<6 hours * Elevated systolic blood pressure (\>140 mmHg) at admission Exclusion Criteria: * Secondary causes of ICH (e.g., trauma, vascular malformation) * Presumed fatal bleeding at admission * Short remaining life expectancy (\<12 month)
Where it's running
-
Aarhus University Hospital
Aarhus, Denmark Recruiting
Study contacts
- Study coordinator: Rolf Blauenfeldt, MD, PhD
- Email: rolfblau@rm.dk
- Phone: +4520774053
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Savvy medication-support program for people after stroke
This project will test whether Savvy — short phone-based psychological exercises, a weekly pill organizer, and text reminders — helps stroke survivors take their blood-pressure medicines and improve blood pressure compared with usual care.
-
AI-assisted transcranial Doppler ultrasound to detect early brain bleeding
This will try to see if a quick transcranial Doppler ultrasound combined with artificial intelligence can detect intracerebral bleeding in adults with suspected acute stroke within 48 hours of symptom onset.
-
Reducing the risk of heart and brain events after intracerebral hemorrhage with aspirin
This trial tests whether giving low-dose aspirin every day after intracerebral hemorrhage can reduce major heart or brain-related events compared with a placebo.
-
Minimally invasive surgery to remove deep (basal ganglia) brain hemorrhages
This observational study will see if minimally invasive surgery helps adults aged 18–80 with spontaneous deep (basal ganglia) intracerebral hemorrhage who present within 72 hours, compared with standard medical care.
-
Stereotactic tenecteplase clot liquefaction for supratentorial intracerebral hemorrhage
This trial will see if stereotactic minimally invasive clot drainage plus a single low dose of tenecteplase helps adults with moderate-to-large supratentorial intracerebral hemorrhage recover better than standard medical care.
-
When and how people recover after an intracerebral hemorrhage
This registry will collect detailed, long-term data on adults who have surgery for intracerebral hemorrhage to see if the timing and type of surgical treatment affect recovery and quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.